Exscientia plc is an artificial intelligence-driven pharmaceutical company focused on discovering, designing, and developing drugs in a fast, efficient manner, with three AI-designed drugs that are in Phase 1 human clinical trials. The foundation invested in the Company to develop five phase 1-ready small molecule therapeutics to help prepare for future pandemics. The collaboration will focus on developing broad-spectrum antivirals for coronaviruses, influenza, and paramyxoviruses.
Investment Date: October 2021